Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

Bronchial Asthma Clinical Trial

Official title:
Multicentre, Multinational, Randomised, Double Blind, Double Dummy, Active Drug Controlled, Parallel Group Study Design Clinical Trial of the Efficacy and Tolerability of Beclomethasone Dipropionate 250 mcg Plus Salbutamol 100 mcg in HFA pMDI Fixed Combination vs. Beclomethasone Dipropionate 250 mcg Plus Salbutamol 100 mcg in CFC pMDI (Clenil® Compositum 250) Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

Status Completed

Clinical Trial Summary

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combination given with the conventional CFC propellant (Clenil® Compositum 250, Chiesi Farmaceutici) in terms of Pulmonary Function (morning PEF).

Clinical Trial Description

Asthma is a chronic inflammatory disorder of the airways and a serious public health worldwide problem, affecting people of all ages, with an estimate of 300 millions affected individuals.When uncontrolled, asthma can place severe limits on daily life, and can sometimes be fatal.

There are two major classes of inhaled therapy for the treatment of reversible obstructive airways disease: antinflammatory agents and bronchodilators. In particular, BDP 250 mcg plus salbutamol 100 mcg in fixed combination is an effective and safe method to control symptoms of persistent asthma in adults.

This study has been designed to compare the efficacy, safety and tolerability of a new BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination with the same CFC-formulated fixed combination, which is on the market from some decades.The HFA propelled product is developed to replace the CFC formulation already marketed according to the European Union's Committee for Proprietary Medicinal Products (CPMP) Note for Guidance (III/5378/93 - Final) in order to prevent from depletion of stratospheric ozone.

The primary objective of this trial is to demonstrate that the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combination given with the conventional CFC propellant (Clenil® Compositum 250, Chiesi Farmaceutici) in terms of Pulmonary Function (morning PEF).

Given the aim of the study, the population to be monitored includes adult patients with persistent asthma according to the current guidelines. The treatment period will be preceded by a 2-week run-in period. Subjects satisfying all the inclusion and exclusion criteria will then enter the 12-week treatment period. Clinic visits will take place at the start and end of the run-in period, and after 2, 4, 8 and 12 weeks after randomisation. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00528723
Study type	Interventional
Source	Chiesi Farmaceutici S.p.A.
Contact
Status	Completed
Phase	Phase 3
Start date	November 2007
Completion date	January 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02934945` - Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients	Phase 4
Completed	`NCT02561351` - Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation	N/A
Recruiting	`NCT01759472` - Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test	N/A
Completed	`NCT01918293` - Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult	N/A
Completed	`NCT01203904` - Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation	N/A
Completed	`NCT01762917` - Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing	N/A
Completed	`NCT00536731` - Symbicort Rapihaler Therapeutic Equivalence Study	Phase 3
Completed	`NCT00930826` - Childhood Asthma and Schooling: The Truth Unveiled	N/A
Completed	`NCT00331929` - Respiratory Health Study of Children in Kiryat Tivon	N/A
Completed	`NCT00327028` - Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma	Phase 4
Completed	`NCT00413387` - Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)	Phase 3
Completed	`NCT00153283` - Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma	Phase 4
Completed	`NCT00950794` - Study of Salmeterol (SN408D) for Adult Asthma	Phase 4
Completed	`NCT00142025` - Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma	Phase 4
Completed	`NCT00153270` - Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma	Phase 4
Completed	`NCT03450434` - XC8 in the Treatment of Patients With Bronchial Asthma	Phase 2
Recruiting	`NCT05189613` - Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis	N/A
Recruiting	`NCT04128111` - Study on the Correlation Between TCM Syndrome, Inflammatory Phenotype and Biomarker of Bronchial Asthma
Completed	`NCT06326632` - Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma	N/A
Completed	`NCT05088512` - The Role of Genetic Factors in the Development of Bronchial Asthma in the Kazakh Population